Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aspirin and breast cancer risk

This article was originally published in The Tan Sheet

Executive Summary

The use of aspirin and other non-steroidal anti-inflammatory drugs and acetaminophen is not associated with a reduced risk of breast cancer among premenopausal women in a study published online in the Internal Archives of Medicine Jan. 26. Led by Harvard researcher A. Heather Eliassen, the trial followed 112,292 women ages 25 to 42 who completed a lifestyle questionnaire for the Nurses' Health Study II in 1989; subjects were followed through 2003. Overall, 1,345 cases of invasive premenopausal breast cancer were documented. Results did not vary by frequency, dose or duration of use. The findings run counter to a meta-analysis published in the Oct. 7 Journal of National Cancer Institute, which concluded NSAIDs, including aspirin and ibuprofen, are associated with a reduced risk of breast cancer (1"The Tan Sheet" Oct. 13, 2008, In Brief)

You may also be interested in...

NSAIDs use may cut breast cancer risk

Non-steroidal anti-inflammatory drug use, including aspirin and ibuprofen, is associated with a reduced risk of breast cancer, according to a meta-analysis published Oct. 7 in the Journal of National Cancer Institute. The review of 38 studies conducted between January 1966 and July 2008 found women using NSAIDs were 12 percent less likely to develop breast cancer than women who did not. Ibuprofen use reduced the risk by 21 percent and aspirin use by 13 percent. The study did not find that higher doses or longer duration - especially of aspirin or ibuprofen - further reduced the risk of breast cancer. Researchers, led by Bahi Takkouche at the University of Santiago de Compostela in Spain, acknowledge weaknesses in the meta-analysis, including not considering other drugs participants took

DJO Thinks Trilliant Is Brilliant, Announces Acquisition

DJO Global will buy Trilliant Surgical to further its ongoing expansion into the US foot and ankle market.

Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race

Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts